TRAIL effect on osteoclast formation in physiological and pathological conditions

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 3, 2011, Pages 1154-1161

  Brunetti, Giacomina ^a   Oranger, Angela ^a   Mori, Giorgio ^b   Sardone, Francesca ^a   Pignataro, Paolo ^a   Coricciati, Marco ^a   Napoli, Nicola ^c   Rizzi, Rita ^a   Liso, Vincenzo ^a   Grassi, Felice Roberto ^a   Grano, Maria ^a   Colucci, Silvia ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Multiple Myeloma; Osteoclastogenesis; Periodontal Disease; TRAIL

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TNFSF10 PROTEIN, HUMAN;

AGED; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERIODONTAL DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; SERUM; CELL DIVISION; CULTURE MEDIUM; CYTOLOGY; MIDDLE AGED; OSTEOCLAST; PATHOLOGY; PHYSIOLOGY;

AGED; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80053580318     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Boyle WJ, WS Simonet, DL Lacey: Osteoclast differentiation and activation. Nature 423, 337-342 (2003) (Pubitemid 40852708)
2. Clowes JA, BL Riggs, S Khosla: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 208, 207-227 (2005) (Pubitemid 41746395)
3. Kim N, Y Kadono, M Takami, J Lee, SH Lee, F Okada, JH Kim, T Kobayashi, PR Odgren, H Nakano, WC Yeh, SK Lee, JA Lorenzo, Y Choi: Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202, 589-595 (2005) (Pubitemid 41248411)
4. Kitaura H, P Zhou, HJ Kim, DV Novack, FP Ross, SL Teitelbaum: M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115, 3418-3427 (2005) (Pubitemid 43121830)
5. Schett G, K Redlich, S Hayer, J Zwerina, B Bolon, C Dunstan, B Görtz, A Schulz, H Bergmeister, G Kollias, G Steiner, JS Smolen: Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48, 2042-2051 (2003) (Pubitemid 36828700)
6. Takayanagi H: Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83, 170-179 (2005) (Pubitemid 40487405)
7. Yang CR, JH Wang, SL Hsieh, SM Wang, TL Hsu, WW Lin: Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 11 Suppl 1, S97-S107 (2004) (Pubitemid 39136802)
8. Colucci S, G Brunetti, G Mori, A Oranger, M Centonze, C Mori, FP Cantatore, R Tamma, R Rizzi, V Liso, A Zallone, M Grano: Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia 23, 2139-2146 (2009)
9. Park H, YK Jung, OJ Park, YJ Lee, JY Choi, Y Choi: Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 175, 7193-7201 (2005) (Pubitemid 41713413)
10. Secchiero P, A Gonelli, P Mirandola, E Melloni, L Zamai, C Celeghini, D Milani, G Zauli: Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 100, 2421-2429 (2002)
11. Secchiero P, E Melloni, M Heikinheimo, S Mannisto, R Di Pietro, A Iacone, G Zauli: TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 103, 517-522 (2004) (Pubitemid 38140081)
12. Zauli G, E Rimondi, V Nicolin, E Melloni, C Celeghini, P Secchiero: TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104, 2044-2050 (2004) (Pubitemid 39297855)
13. Yen ML, HF Tsai, YY Wu, HL Hwa, BH Lee, PN Hsu: TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. Mol Immunol 45, 2205-2213 (2008)
14. Labrinidis A, V Liapis, le M Thai, GJ Atkins, C Vincent, S Hay, NA Sims, AC Zannettino, DM. Findlay, A Evdokiou: Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood 111, 5411-5412 (2008)
15. Nicolin V, P Narducci, C Celeghini: Effect of recombinant TRAIL in a murine co-culture system of osteoclastogenesis. Eur J Histochem 52, 75-78 (2008)
16. Zauli G, E Rimondi, S Stea, F Baruffaldi, M Stebel, C Zerbinati, F Corallini, P Secchiero: TRAIL inhibits osteoclastic differentiation by counteracting RANKLdependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214, 117-125 (2008) (Pubitemid 350220065)
17. Roux S, P Lambert-Comeau, C Saint-Pierre, M Lépine, B Sawan, JL Parent: Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 333, 42-50 (2005) (Pubitemid 40813444)
18. Colucci S, G Brunetti, FP Cantatore, A Oranger, G Mori, P Pignataro, R Tamma, FR. Grassi, A Zallone, M Grano: The death receptor DR5 is involved in TRAILmediated human osteoclast apoptosis. Apoptosis 12, 1623-1632 (2007) (Pubitemid 47106894)
19. Zauli G, P Secchiero: The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17, 245-257 (2006) (Pubitemid 44038614)
20. Holen I, PI Croucher, FC Hamdy, CL Eaton: Osteoprotegerin is a survival factor for human prostate cancer cell. Cancer Res 62, 1619-1623 (2002) (Pubitemid 34408480)
21. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63, 912-916 (2003) (Pubitemid 36278418)
22. Colucci S, G Brunetti, R Rizzi, A Zonno, G Mori, G Colaianni, D Del Prete, R Faccio, A Liso, S Capalbo, V Liso, A Zallone, M Grano: T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104, 3722-3730 (2004) (Pubitemid 39564450)
23. Neville-Webbe HL, NA Cross, CL Eaton, R Nyambo, CA Evans, RE Coleman, I Holen: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86, 269-279 (2004) (Pubitemid 39070969)
24. Sandra F, L Hendarmin, S Nakamura: Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosisinducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol; 42, 415-420 (2006)
25. Miyashita T, A Kawakami, T Nakashima, S Yamasaki, M Tamai, F Tanaka, M Kamachi, H Ida, K Migita, T Origuchi, K Nakao, K Eguchi: Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factorrelated apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 137, 430-436 (2004) (Pubitemid 39013092)
26. Neville-Webbe HL, NA Cross, CL Eaton, R Nyambo, CA Evans, RE Coleman, I Holen: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86, 269-279 (2004) (Pubitemid 39070969)
27. Mori G, G Brunetti, S Colucci, F Ciccolella, M Coricciati, P Pignataro, A Oranger, A Ballini, D Farronato, F Mastrangelo, S Tetè, FR Grassi, M Grano: Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL. J Biol Regul Homeost Agents 21,105-114 (2007) (Pubitemid 351524044)
28. Brunetti G, S Colucci, P Pignataro, M Coricciati, G Mori, N Cirulli, A Zallone, FR Grassi, M Grano: T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. J Periodontol 76, 1675-1680 (2005) (Pubitemid 41645576)
29. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121, 749-757 (2003)
30. Greipp PR, J San Miguel, BG Durie, JJ Crowley, B Barlogie, J Bladé, M Boccadoro, JA Child, H Avet-Loiseau, RA Kyle, JJ Lahuerta, H Ludwig, G Morgan, R Powles, K Shimizu, C Shustik, P Sonneveld, P Tosi, I Turesson, J Westin: International staging system for multiple myeloma. J Clin Oncol 23, 3412-3420 (2005)
31. Löe H: The gingival index, plaque index and the retention index systems. J Periodontol 38, 610-616 (1967)
32. Benn DK: Review of the reliability of radiographic measurements in estimating alveolar bone changes. J Clin Periodontol 17, 14-21 (1990) (Pubitemid 20019368)
33. Lang NP, RG Hill: Radiographs in periodontics. J Clin Periodontol 4, 16-28 (1977) (Pubitemid 8038497)
34. Zauli G, E Rimondi, C Celeghini, D Milani, P Secchiero: Dexamethasone counteracts the antiosteoclastic, but not the anti-leukemic, activity of TNFrelated apoptosis inducing ligand (TRAIL) J Cell Physiol 222, 357-364 (2010)
35. Vitovski S, JS Phillips, J Sayers, PI Croucher: Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282, 31601-31609 (2007) (Pubitemid 350044899)
36. Hofbauer LC, M Schoppet, M Christ, J Teichmann, U Lange: Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford) 45, 1218-1222 (2006) (Pubitemid 44542061)
37. Zai-Xing Y, L Yan, W Hao, Z Ye, L Chang, Z Ren-Qian: Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis. J Clin Lab Anal 22, 138-145 (2008) (Pubitemid 351543946)
38. Xie YD, L Jin, QW Yu: The role of IFN-gamma, IL-10, IL-12 and TRAIL in sera and synovium fluids from patients with rheumatoid arthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23, 536-537 (2007)